The market is illiquid simple as that. $600 in volume lights the board up?
Q4 has a key phase 2 human clinical funded by DOD coming up where success parlays into much more for the ampakine platform. And they are speaking at a cannabanoid conference in November which relates to their OSA program which is overdue for an update. Plus they hired a consultant group applying for grant funding for the third platform with KRM-ll-81 which we have yet to hear an update on the NIH tier 3 preclinicals and grant funding couild be know early as late this year is my guess.
Market Data 
Markets 
AI
